Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28571196 | 0.85 | — | — | |
| SCHEMBL11700024 | 0.79 | LDHA (0.32) | KDM4ETSHR | |
| SCHEMBL4317415 | 0.76 | TSHR (0.32) | KDM4ETSHR | |
| SCHEMBL17656831 | 0.76 | TSHR (0.32) | KDM4ETSHR | |
| SCHEMBL28134068 | 0.74 | TSHR (0.35) | KDM4ETSHR | |
| SCHEMBL10883792 | 0.74 | GRIK1 (0.31) | KDM4ETSHR | |
| SCHEMBL6454939 | 0.74 | CYP1A2 (0.37) | KDM4ETSHR | |
| SCHEMBL2905913 | 0.74 | CYP1A2 (0.37) | KDM4ETSHR | |
| SCHEMBL2416426 | 0.72 | KDM4E (0.33) | KDM4ETSHR | |
| SCHEMBL346751 | 0.72 | KDM4E (0.33) | KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2413937-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | KDM4E 1873/4885TSHR 4162/4885 |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | KDM4E 2296/4885TSHR 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.